The ROE as of December 2024 (TTM) for Xilio Therapeutics, Inc. (XLO) is -214.74%

According to Xilio Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -214.74%. This represents a change of 284.80% compared to the average of -55.81% of the last 4 quarters.

Xilio Therapeutics, Inc. (XLO) Historical ROE (quarterly & annually)

How has XLO ROE performed in the past?

The mean historical ROE of Xilio Therapeutics, Inc. over the last ten years is -41.05%. The current -214.74% ROE has changed 423.18% with respect to the historical average. Over the past ten years (40 quarters), XLO's ROE was at its highest in in the December 2020 quarter at 24.94%. The ROE was at its lowest in in the September 2024 quarter at -66.84%.

Xilio Therapeutics, Inc. (XLO) ROE by Quarter and Year

Discovering the peaks and valleys of Xilio Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xilio Therapeutics, Inc. (XLO) Average ROE

How has XLO ROE performed in the past?

The current ROE of Xilio Therapeutics, Inc. (XLO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Xilio Therapeutics, Inc. (XLO) ROE vs. Peers

How is XLO’s ROE compared to its peers?

Xilio Therapeutics, Inc.’s ROE is less than Connect Biopharma Holdings Limited (7.21%), greater than Tyra Biosciences, Inc. (-25.14%), greater than RAPT Therapeutics, Inc. (-89.09%), greater than Mineralys Therapeutics, Inc. (-55.92%), less than Edgewise Therapeutics, Inc. (0%), greater than Ikena Oncology, Inc. (-26.83%), greater than Design Therapeutics, Inc. (-39.59%), greater than Eliem Therapeutics, Inc. (-18.01%), less than Anebulo Pharmaceuticals, Inc. (0%), greater than AN2 Therapeutics, Inc. (-184.40%), greater than Aerovate Therapeutics, Inc. (-57.63%), greater than Adagene Inc. (-90.19%), greater than Molecular Partners AG (-50.10%), greater than MediciNova, Inc. (-39.16%), greater than Champions Oncology, Inc. (-20.70%), less than Cyteir Therapeutics, Inc. (66.22%), greater than null (-9.44%),

Build a custom stock screener for Xilio Therapeutics, Inc. (XLO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xilio Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xilio Therapeutics, Inc. (XLO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xilio Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.